Melanoma pp 157-182 | Cite as

Melanoma Antigens

Vaccines and Monoclonal Antibodies
  • Paul B. Chapman
  • Jedd D. Wolchok
Part of the Current Clinical Oncology book series (CCO)


Physicians have been intrigued with the idea of immunizing against cancer well before there was any coherent understanding of immune mechanisms. The most simple approach seemed to be to inject subjects with crude tumor material, and there have been well over a hundred reports from 1902 through 1990 of patients being injected with tumor extracts (1) .Few of these reports are interpretable, however. Early studies in the 1950s using inbred strains of mice showed that among chemically induced tumors, there were tumor-specific antigens that could serve as tumor rejection antigens (2,3) .However, experiments by Hewitt and colleagues demonstrated that spontaneously arising tumors, such as those seen in patients, are far less immunogenic than chemically induced tumors making it unclear whether these observations could be extended to spontaneously arising tumors (4) .This generated a question and controversy, which persists today; namely, do experiments using inbred strains of mice and tumor cell lines from artificially induced tumors have relevance to the clinical setting?


Major Histocompatibility Complex Class Metastatic Melanoma Melanoma Patient Peptide Vaccine Melanoma Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Oettgen HF, Old LJ. The history of cancer immunotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds., Biologic Therapy of Cancer. J.B. Lippincott Company, Philadelphia, 1991, pp. 87–120.Google Scholar
  2. 2.
    Foley E. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 1953; 13: 835–837.PubMedGoogle Scholar
  3. 3.
    Prehn RT, Main JM Immunity to methylcholanthrene-induced sarcomas. JNatl Cancer Inst 1957; 18: 769–778.Google Scholar
  4. 4.
    Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 1976; 33: 241–259.PubMedCrossRefGoogle Scholar
  5. 5.
    Old LJ. Cancer immunology: the search for specificity-G.H.A. Clowes memorial lecture. Cancer Res 1981; 41: 361–375.PubMedGoogle Scholar
  6. 6.
    Nasi M, Meyers M, Livingston P, Houghton A, Chapman P. Anti-melanoma effects of R24, a monoclonal antibody against GD3. Vaccine Res 1997; 7 (suppl 2): S155 - S162.Google Scholar
  7. 7.
    Creekmore S, Urba W, Koop W, et al. Phase IB/II trial of R24 antibody and interleukin-2 (IL2) in melanoma. Proc Am Soc Clin Oncol 1992; 11: 345.Google Scholar
  8. 8.
    Bajorin DF, Chapman PB, Dimaggio J, et al. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 1990; 50: 7490–7495.PubMedGoogle Scholar
  9. 9.
    Minasian LM, Szatrowski TP, Rosenblum M, et al. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-a and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood 1994; 83: 56–64.PubMedGoogle Scholar
  10. 10.
    Livingston PO, Takeyama H, Pollack MS, et al. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Int J Cancer 1983; 31: 567–575.PubMedCrossRefGoogle Scholar
  11. 11.
    Gercovich FG, Gutterman JU, Mavligit GM, Hersh EM. Active specific immunization in malignant melanoma. Med Pediatr Oncol 1975; 1: 277–287.PubMedCrossRefGoogle Scholar
  12. 12.
    Slingluff CL Jr, Seigler HF. Immunotherapy for malignant melanoma with a tumor cell vaccine. Ann Plast Surg 1992; 28: 104–107.PubMedCrossRefGoogle Scholar
  13. 13.
    Morton DL, Foshag LJ, Nizze JA, et al. Active specific immunotherapy in malignant melanoma. Semin Surg Oncol 1989; 5: 420–425.PubMedCrossRefGoogle Scholar
  14. 14.
    Haigh PI, Difronzo LA, Gammon G, Morton DL. Vaccine therapy for patients with melanoma. Oncology (Huntingt) 1999; 13: 1561–1574.Google Scholar
  15. 15.
    Chan AD, Morton DL. Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol 1998; 25: 611–622.PubMedGoogle Scholar
  16. 16.
    Bystryn JC, Henn M, Li J, Shroba S. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res 1992; 52: 5948–5953.PubMedGoogle Scholar
  17. 17.
    Bystryn JC. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens. Ann NY Acad Sci 1993; 690: 190–203.PubMedCrossRefGoogle Scholar
  18. 18.
    Okamoto T, Irie RF, Fujii S, et al. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 1998; 111: 1034–1039.PubMedCrossRefGoogle Scholar
  19. 19.
    Huang SK, Okamoto T, Morton DL, Hoon DS. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J Invest Dermatol 1998; 111: 662–667.PubMedCrossRefGoogle Scholar
  20. 20.
    Reynolds SR, Celis E, Sette A, et al. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol 1998; 161: 6970–6976.PubMedGoogle Scholar
  21. 21.
    Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine [published erratum appears in Ann Surg 1993 Mar; 217(3): 309]. Ann Surg 1992; 216: 463–482.PubMedCrossRefGoogle Scholar
  22. 22.
    Bystryn JC. Clinical activity of a polyvalent melanoma antigen vaccine. Recent Results Cancer Res 1995; 139: 337–348.PubMedCrossRefGoogle Scholar
  23. 23.
    Mitchell MS, Von Eschen KB. Phase III trial of melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma. Proc Am Soc Clin Oncol 1997; 16: 494a.Google Scholar
  24. 24.
    Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. JAm Coll Surg 1998; 187: 69–77.CrossRefGoogle Scholar
  25. 25.
    Berd D, Murphy G, Maguire HC, Mastrangelo MJ. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res 1991; 51: 2731–2734.PubMedGoogle Scholar
  26. 26.
    Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cell engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 35339–33543.CrossRefGoogle Scholar
  27. 27.
    Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95: 13141–13146.PubMedCrossRefGoogle Scholar
  28. 28.
    Ellem KA, O’Rourke MG, Johnson GR, et al. A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997; 44: 10–20.PubMedCrossRefGoogle Scholar
  29. 29.
    Dranoff G, Soiffer R, Lynch T, et al. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther 1997; 8: 111–123.PubMedCrossRefGoogle Scholar
  30. 30.
    Hamilton WB, Helling F, Lloyd KO, Livingston PO. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 1993; 53: 566–573.PubMedCrossRefGoogle Scholar
  31. 31.
    Jones PC, Lan LS, Liu PY, Morton DL, Irie RF. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 1981; 66: 249–254.PubMedGoogle Scholar
  32. 32.
    Livingston PO, Wong GYC, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 1036–1044.PubMedGoogle Scholar
  33. 33.
    Helling F, Zhang S, Shang A, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995; 55: 2783–2788.PubMedGoogle Scholar
  34. 34.
    Chapman PB, Morrissey DM, Panageas KS, et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-KLH + QS21 vaccine: a dose-response study. Clin Cancer Res 2000; 6: 874–879.PubMedGoogle Scholar
  35. 34a.
    Kirkwood JM, Ibrahim JG, Sosman JA, et al. J. Clin. Oncol. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS21 vaccine in patients withresected stage IIB-III melanoma: results of intergroup trial E1694/ S9512/C509801. 2001; 19: 2370–2380.Google Scholar
  36. 35.
    Chapman PB, Morrissey D, Ibrahim J, et al. Eastern Cooperative Oncology Group Phase II randomized adjuvant trial of GM2-KLH + QS21 (GMK) vaccine ± high dose interferon 2b in melanoma. Proc Am Soc Clin Oncol 1999; 17: 538a.Google Scholar
  37. 36.
    Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 1985; 35: 607–612.PubMedCrossRefGoogle Scholar
  38. 36a.
    Chapman PB, Morrisey D, Panageas KS, et al. Vaccination with a bivalent GM2 and GD2 ganglioside conjugate vaccine: A trial comparing doses of GD2-KLH. Clin Cancer Res 2000; 6: 4658–4662.PubMedGoogle Scholar
  39. 37.
    Ritter G, Boosfeld E, Adluri R, et al. Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int J Cancer 1991; 48: 379–385.PubMedCrossRefGoogle Scholar
  40. 38.
    Ragupathi G, Meyers M, Adluri S, Howard L, Musselli L, Livingston PO. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactoneKLH conjugate plus immunological adjuvant QS-21. Int J Cancer 2000; 85: 659–666.PubMedCrossRefGoogle Scholar
  41. 39.
    Cheung N-KV, Canete A, Cheung IY, Ye J-N, Liu C. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Mt J Cancer 1993; 54: 499–505.Google Scholar
  42. 40.
    Saleh MN, Stapleton JD, Khazaeli MB, LoBuglio AF. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J Immunol 1993; 151: 3390–3398.PubMedGoogle Scholar
  43. 41.
    Sen G, Chakraborty M, Foon KA, Reisfeld RA, Bhattacharya-Chatterjee M. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. Clin Cancer Res 1997; 3: 1969–1976.PubMedGoogle Scholar
  44. 42.
    Foon KA, Lutzky J, Baral RN, et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 2000; 18: 376–384.PubMedGoogle Scholar
  45. 43.
    Yao T-J, Meyers M, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2-Keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 1999; 5: 77–81.PubMedGoogle Scholar
  46. 44.
    McCaffery M, Yao T-J, Williams L, Livingston PO, Houghton AN, Chapman PB. Enhanced immunogenicity of BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside when combined with adjuvant. Clin Cancer Res 1996; 2: 679–686.PubMedGoogle Scholar
  47. 45.
    Tai T, Paulson JC, Cahan LD, Irie RF. Ganglioside GM2 as a human tumor antigen (OFAI-1). Proc Natl Acad Sci USA 1983; 80: 5392–5396.PubMedCrossRefGoogle Scholar
  48. 46.
    Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus BCG. Clin Cancer Res 1999; 5: 1319–1324.PubMedGoogle Scholar
  49. 47.
    Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178: 489–495.PubMedCrossRefGoogle Scholar
  50. 48.
    Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180: 35–42.PubMedCrossRefGoogle Scholar
  51. 49.
    Wolfel T, Hauer M, Schneider J, et al. A pl6INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281–1284.PubMedCrossRefGoogle Scholar
  52. 50.
    Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990; 171: 1375–1380.PubMedCrossRefGoogle Scholar
  53. 51.
    Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184: 2207–2216.PubMedCrossRefGoogle Scholar
  54. 52.
    Chen YT, Old LJ. Cancer-testis antigens: targets for cancer immunotherapy [comment]. Cancer J Sci Am 1999; 5: 16–17.PubMedCrossRefGoogle Scholar
  55. 53.
    van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643–1647.PubMedCrossRefGoogle Scholar
  56. 54.
    Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996; 157: 2539–2548.PubMedGoogle Scholar
  57. 55.
    Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998; 188: 1553–1561.PubMedCrossRefGoogle Scholar
  58. 56.
    Topalian SL, Gonzales MI, Parkhurst M, et al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996; 183: 1965–1971.PubMedCrossRefGoogle Scholar
  59. 57.
    Jager E, Jager D, Karbach J, et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101–0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 2000; 191: 625–630.PubMedCrossRefGoogle Scholar
  60. 58.
    Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80: 219–230.PubMedCrossRefGoogle Scholar
  61. 59.
    Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A phase I trial of an HLA-A 1 restricted MAGE-3 epitope peptide with incomplete Freund’s adjuvant in patients with resected high-risk melanoma. J Immunother 1999; 22: 431–440.PubMedCrossRefGoogle Scholar
  62. 60.
    Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5: 677–685.PubMedCrossRefGoogle Scholar
  63. 61.
    Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp 100 following patient immunization with synthetic peptide. Cancer Res 1996; 56: 4749–4757.PubMedGoogle Scholar
  64. 62.
    Jaeger E, Bernhard H, Romero P, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. lilt J Cancer 1996; 66: 162–169.Google Scholar
  65. 63.
    Storkus WJ, Kirkwood JM, Mayordomo JI, et al. Melanoma peptide vaccine: a randomized Phase I evaluation of MART-1, gp100, and tyrosinase peptide vaccines in patients with malignant melanoma [meeting abstract]. Proc Annu Meet Am Soc Clin Oncol 1996; 15: A1811.Google Scholar
  66. 64.
    Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma [see comments]. Nat Med 1998; 4: 321–7.PubMedCrossRefGoogle Scholar
  67. 65.
    Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine in incomplete Freund’s adjuvant for resected high-risk melanoma. Clin Cancer Res 1999; 5: 2756–2765.PubMedGoogle Scholar
  68. 66.
    Jager E, Ringhoffer M, Dienes HP, et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. IntJCancer 1996; 67: 54–62.Google Scholar
  69. 67.
    Zarour HM, Kirkwood JM, Kierstead LS, et al. Melan-A/MART-1(51–73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci USA 2000; 97: 400–405.PubMedCrossRefGoogle Scholar
  70. 68.
    Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J 1997; 3: 37–44.Google Scholar
  71. 69.
    Lee K-H, Wang E, Nielsen MB, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163: 6292–6300.PubMedGoogle Scholar
  72. 70.
    Wolfel T, Hauer M, Schneider J, et al. A p164-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281–1284.PubMedCrossRefGoogle Scholar
  73. 71.
    Robbins PF, El-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996; 183: 1185–1192.PubMedCrossRefGoogle Scholar
  74. 72.
    Chiari R, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res 1999; 59: 5785–5792.PubMedGoogle Scholar
  75. 73.
    Coulie PG, Lehmann F, Lethe B, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995; 92: 7976–7980.PubMedCrossRefGoogle Scholar
  76. 74.
    Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class H-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999; 284: 1351–1354.PubMedCrossRefGoogle Scholar
  77. 75.
    Weeratna RD, McCluskie MJ, Xu Y, Davis HL. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000; 18: 1755–1762.PubMedCrossRefGoogle Scholar
  78. 76.
    Kaplan G, Walsh G, Guido LS, et al. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 1992; 175: 1717–1728.PubMedCrossRefGoogle Scholar
  79. 77.
    Schaed SG, Houghton AN, Klimek VM, et al. Immunization of melanoma patients with both tyrosinase (370D) and GP100 (210M) peptides: comparison of adjuvants and peptide immunogenicity. Proc Am Assoc Cancer Res 1999; 41: 4029.Google Scholar
  80. 78.
    Old LJ, Chen Y-T. New paths in human cancer serology. J Exp Med 1998; 187: 1163–1167.PubMedCrossRefGoogle Scholar
  81. 79.
    Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis an. J Exp Med 1998; 187: 265–270.PubMedCrossRefGoogle Scholar
  82. 80.
    Jager E, Maeurer M, Hohn H, et al. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer 2000; 86: 538–547.PubMedCrossRefGoogle Scholar
  83. 81.
    Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998; 188: 1075–1082.PubMedCrossRefGoogle Scholar
  84. 82.
    Casares S, Inaba K, Brumeanu TD, Steinman RM, Bona CA. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med 1997; 186: 1481–1486.PubMedCrossRefGoogle Scholar
  85. 83.
    Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 1999; 189: 169–178.PubMedCrossRefGoogle Scholar
  86. 84.
    Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996; 93: 2879–2883.PubMedCrossRefGoogle Scholar
  87. 85.
    Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273: 352–354.PubMedCrossRefGoogle Scholar
  88. 86.
    Bowne WB, Srinivasan R, Wolchok JD, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999; 190: 1717–1722.PubMedCrossRefGoogle Scholar
  89. 87.
    Hawkins WG, Gold JS, Dyall R, et al. Immunization with DNA coding for gp 100 results in CD4+ T-cell independent antitumor immunity. Surgery 2001; 128: 273–280.CrossRefGoogle Scholar
  90. 88.
    Weber LW, Bowne WB, Wolchok JD, et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998; 102: 1258–1264.PubMedCrossRefGoogle Scholar
  91. 89.
    Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282: 476–480.PubMedCrossRefGoogle Scholar
  92. 90.
    Boyer JD, Cohen AD, Vogt S, et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis 2000; 181: 476–483.PubMedCrossRefGoogle Scholar
  93. 91.
    Ugen KE, Nyland SB, Boyer JD, et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine 1998; 16: 1818–1821.PubMedCrossRefGoogle Scholar
  94. 92.
    Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells [see comments]. Nat Med 1998; 4: 328–332.PubMedCrossRefGoogle Scholar
  95. 93.
    Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669–1678.PubMedCrossRefGoogle Scholar
  96. 94.
    Nasi ML, Lieberman P, Busam KJ, et al. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. Cytokines Cell Mol Ther 1999; 5: 139–144.PubMedGoogle Scholar
  97. 95.
    Bowne WB, Wolchok JD, Hawkins WG, et al. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines Cell Mol Ther 1999; 5: 217–225.PubMedGoogle Scholar
  98. 96.
    Przepiorka D, Srivastava PK. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol Med Today 1998; 4: 478–484.PubMedCrossRefGoogle Scholar
  99. 97.
    Srivastava PK. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods 1997; 12: 165–171.PubMedCrossRefGoogle Scholar
  100. 98.
    Blachere NE, Srivastava PK. Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin Cancer Biol 1995; 6: 349–355.PubMedCrossRefGoogle Scholar
  101. 99.
    Srivastava PK, Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol 1994; 6: 728–732.PubMedCrossRefGoogle Scholar
  102. 100.
    Eton O, East MJ, Ross MI, et al. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients (pts) with metastatic melanoma. ProcAmAssoc Cancer Res 2000; 41: 3463.Google Scholar
  103. 101.
    Vadhan-Raj S, Cordon-Cardo C, Carswell EA, et al. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 1988; 6: 1636–1648.PubMedGoogle Scholar
  104. 102.
    Bajorin DF, Chapman PB, Wong GY, et al. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res 1992; 2: 355–362.PubMedCrossRefGoogle Scholar
  105. 103.
    Raymond J, Kirkwood J, Vlock D, et al. A phase Ib trial of murine monoclonal antibody R24 (anti-GD3) in metastatic melanoma. Proc Am Soc Clin Oncol 1991; 10: 298.Google Scholar
  106. 104.
    Dippold WG, Bernhard H, Dienes HP, Meyer zum Buschenfeld K-H. Treatment of patients with malignant melanoma by monoclonal ganglioside antibodies. Eur J Cancer Clin Oncol 1988; 24 (suppl 2): 865–867.Google Scholar
  107. 105.
    Dippold W, Bernhard H, Meyer zum Buschenfelde KH Immunological response to intrathecal and systemic treatment with ganglioside antibody R-24 in patients with malignant melanoma. Eur J Cancer 1994; 30A: 137–144.CrossRefGoogle Scholar
  108. 106.
    Bukowski RM, Murthy SA, Finke J, et al. Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects. J Immunother 1994; 15: 273–282.CrossRefGoogle Scholar
  109. 107.
    Cheung N, Lazarus H, Miraldi F, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma [published erratum appears in J Clin Oncol 1992 April 10(4): 671]. J Clin Oncol 1987; 5: 1430–1440.PubMedGoogle Scholar
  110. 108.
    Cheung N-KV, Lazarus H, Miraldi FD, et al. Reassessment of patient response to monoclonal antibody 3F8. J Clin Oncol 1992; 10: 671–672.PubMedGoogle Scholar
  111. 109.
    Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992; 52: 4342–4347.PubMedGoogle Scholar
  112. 110.
    Murray JL, Cunningham JE, Brewer H, et al. Phase I trial of mouse monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994; 12: 184–193.PubMedGoogle Scholar
  113. 111.
    Saleh MN, Khazaeli MD, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 1992; 3: 19–23.PubMedGoogle Scholar
  114. 112.
    Lichtin A, Iliopoulos D, Guerry D, Elder D, Herlyn D, Steplewski Z. Therapy of melanoma with an anti-melanoma ganglioside monoclonal antibody: a possible mechanism of a complete response. Proc Am Soc Clin Oncol 1988; 7: 247.Google Scholar
  115. 113.
    Lonberg M, Bajorin D, Cheung N-K, et al. Phase I trial of a combination of two mouse monoclonal antibodies anti-GD3 (R24) and anti-GD2 (3F8) in patients with melanoma and soft tissue sarcoma. Proc Am Soc Clin Oncol 1988; 7: 173.Google Scholar
  116. 114.
    Albertini M, Hank J, Schiller J, et al. Phase Ib trial of combined treatment with ch 14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Proc Am Soc Clin Oncol 1998; 17: 437a.Google Scholar
  117. 115.
    Ritter G, Ritter-Boosfeld E, Adluri R, et al. Analysis of the antibody response to immunization with purified 0-acetyl GD3 gangliosides in patients with malignant melanoma. Mt J Cancer 1995; 62: 668–672.Google Scholar

Copyright information

© Humana Press Inc.,Totowa, NJ 2002

Authors and Affiliations

  • Paul B. Chapman
  • Jedd D. Wolchok

There are no affiliations available

Personalised recommendations